Alpha Cognition Inc. reported that on November 12, 2024, they entered into an underwriting agreement with Titan Partners Group LLC concerning the sale of their common shares and/or pre-funded warrants. The company completed the offering the following day, issuing common shares for approximately $46.15 million net proceeds, which may reach $52.48 million if underwriters exercise additional purchase options. These funds will support the commercialization of ZUNVEYL in AD, product development, manufacturing activities, and general corporate requirements. Warrants were also issued to the underwriters, exercisable at $7.18 per share beginning on May 8, 2025.
Names and Entities: - Alpha Cognition Inc. - Titan Partners Group LLC - American Capital Partners, LLC - ZUNVEYL - AD (Alzheimer's Disease)